BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported ...
BOSTON, April 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat ...
TransCode’s RIG-I agonist precursor comprises single-stranded 5’-uncapped biphosphate or triphosphate oligonucleotides having a sequence complementary to an endogenous microRNA. The precursor may be ...
BOSTON, April 27, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する